VivoSeq
Hematology

Allogeneic Hematopoietic Stem Cell Transplant Recipient

6

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Allogeneic Hematopoietic Stem Cell Transplant Recipient is an early-stage landscape with 6 programs across 6 companies. The most active players are Avyxa, Prism Pharmaceuticals, Veloxis Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 1P

Prism Pharmaceuticals

1 program

Phase 1V

Veloxis Pharmaceuticals

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting2 · 29%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Monitoring of Measles-specific Immune Status in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients
Recruiting·HHospices Civils de Lyon·N/A·NCT05947864·60 enrolled
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Recruiting·LLoyola University·Phase 2·NCT05554068·100 enrolled
A Randomized Pilot Study of Human Lysozyme Goat Milk in Recipients of Standard Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT04177004·52 enrolled
Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Completed·Novartis logoNovartis·Phase 4·NCT01335035·30 enrolled
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03565900·277 enrolled
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Completed·Pfizer logoPfizer·Phase 3·NCT00980655·251 enrolled
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT02137772·570 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)